Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia

Status Completed

Clinical Trial Summary

It has been proposed that the rapid gastric emptying of carbohydrate containing fluids into the intestine causes hyperglycemia followed by reactive hypoglycemia. The investigators have shown that glucagon-like peptide-1 (GLP-1) secretion in response to a glucose load is increased in children with Post-prandial hypoglycemia (PPH). This is a proof of concept study to investigate the causative role of GLP-1 in the pathophysiology of PPH after fundoplication by evaluating the effects of GLP-1 receptor antagonism on metabolic variables after a mixed meal.

Hypothesis: In children with post-prandial hypoglycemia after fundoplication, antagonism of the GLP-1 receptor by exendin-(9-39) will elevate nadir blood glucose levels after a meal challenge and prevent post-prandial hypoglycemia.

Clinical Trial Description

PPH is a frequent complication of fundoplication in children. The mechanism responsible for the PPH is poorly understood, but involves an exaggerated insulin response to a meal and subsequent hypoglycemia. We have shown that children with PPH after Nissen fundoplication have abnormally exaggerated secretion of GLP-1, an incretin hormone with multiple glucose lowering effects including stimulation of insulin secretion and suppression of glucagon secretion. In this study we seek to examine the causal role of endogenous GLP-1 in PPH after fundoplication by evaluating the effects of antagonizing the GLP-1 receptor with exendin-(9-39) on key metabolic features of PPH. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01162499
Study type	Interventional
Source	Children's Hospital of Philadelphia
Contact
Status	Completed
Phase	N/A
Start date	April 2010
Completion date	December 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03984370` - Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass	Phase 2
Completed	`NCT03200782` - Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study	N/A
Recruiting	`NCT05036317` - Empagliflozin for the Treatment of Postprandial Hypoglycemia	Phase 3
Active, not recruiting	`NCT05174507` - Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes	Phase 2
Completed	`NCT04330196` - Effect of Postprandial Hyperinsulinaemic Hypoglycaemia on Driving Performance.	N/A
Recruiting	`NCT04720859` - Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB)	N/A
Completed	`NCT05676385` - Glucose Response to a Formula for Patients at Risk of Hypoglycaemia	N/A
Completed	`NCT04836273` - Treatment of Post-bariatric Hypoglycaemia	Phase 2
Completed	`NCT05513404` - The Scottish Fruit Study	N/A
Recruiting	`NCT05401578` - Canakinumab for the Treatment of Postprandial Hypoglycemia	Phase 3